Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans

NCT02691429 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-06-07

No results posted yet for this study

Summary

Our research group tested the toxicity of different dye concentrations extracted from the acai fruit using a rabbit model. The dye extracted from the acai fruit in concentrations of 10% and 25% was found to be safe for vitreoretinal surgery. This initial research represented the landmark research for testing this alternative vital dye in a clinical research in humans.

The aim of the present clinical trial in humans will be to test the applicability of the acai dye in the identification of the posterior hyaloid and ILM during vitreoretinal surgery in humans.

Conditions

Interventions

OTHER

Acai dye 10%

dye to be used during chromovitrectomy in humans

Sponsors & Collaborators

  • Rafael R. Caiado

    collaborator UNKNOWN
  • Casa de Saúde São José

    collaborator OTHER
  • Acácio Alves Souza Lima-Filho

    collaborator UNKNOWN
  • Eduardo Novais

    collaborator UNKNOWN
  • Emmerson Badaró

    collaborator UNKNOWN
  • André Maia

    collaborator UNKNOWN
  • Rita Sinigaglia-Coimbra

    collaborator UNKNOWN
  • Sung Eun S. Watanabe

    collaborator UNKNOWN
  • Eduardo B. Rodrigues

    collaborator UNKNOWN
  • Michel Eid Farah

    collaborator UNKNOWN
  • Mauricio Maia

    collaborator UNKNOWN
  • Federal University of São Paulo

    lead OTHER

Principal Investigators

  • Mauricio Maia · Federal University of São Paulo UNIFESP

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-11-30
Completion
2017-05-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02691429 on ClinicalTrials.gov